相似文献
1
Frequency and implications of ofloxacin resistance among previously treated tuberculosis patients.
J Epidemiol Glob Health. 2017 Sep;7(3):207-208. doi: 10.1016/j.jegh.2017.05.003. Epub 2017 May 24.
2
In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis.
Ann Saudi Med. 2005 Sep-Oct;25(5):409-12. doi: 10.5144/0256-4947.2005.409.
3
Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India.
J Chemother. 2007 Apr;19(2):166-71. doi: 10.1179/joc.2007.19.2.166.
4
Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
Tuberculosis (Edinb). 2012 Sep;92(5):404-6. doi: 10.1016/j.tube.2012.05.010. Epub 2012 Jul 11.
5
Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10.
J Antimicrob Chemother. 2011 Oct;66(10):2437-8. doi: 10.1093/jac/dkr302. Epub 2011 Jul 27.
6
Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey.
J Antimicrob Chemother. 2007 May;59(5):1031-3. doi: 10.1093/jac/dkm038. Epub 2007 Feb 28.
7
Utility of fluoroquinolones in multidrug-resistant tuberculosis (MDR-TB)--a balanced view?
Int J Tuberc Lung Dis. 2002 Feb;6(2):174-5; author reply 175-6.
8
Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.
J Clin Microbiol. 2005 Apr;43(4):1612-6. doi: 10.1128/JCM.43.4.1612-1616.2005.
9
Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
Int J Infect Dis. 2008 Mar;12(2):152-6. doi: 10.1016/j.ijid.2007.05.003. Epub 2007 Oct 18.
10
High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India.
PLoS One. 2015 Mar 4;10(3):e0117421. doi: 10.1371/journal.pone.0117421. eCollection 2015.
引用本文的文献
1
A Saudi Arabian Public Health Perspective of Tuberculosis.
Int J Environ Res Public Health. 2021 Sep 24;18(19):10042. doi: 10.3390/ijerph181910042.
本文引用的文献
1
Pyrazinamide resistance among drug-resistant Mycobacterium tuberculosis isolates at a referral hospital.
Diagn Microbiol Infect Dis. 2013 Dec;77(4):380-1. doi: 10.1016/j.diagmicrobio.2013.08.014. Epub 2013 Sep 26.
2
Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
Tuberculosis (Edinb). 2012 Sep;92(5):404-6. doi: 10.1016/j.tube.2012.05.010. Epub 2012 Jul 11.
3
Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.
Eur Respir J. 2012 Oct;40(4):814-22. doi: 10.1183/09031936.00036812. Epub 2012 May 31.
4
Assessment of trends of ofloxacin resistance in Mycobacterium tuberculosis.
Indian J Med Microbiol. 2011 Jul-Sep;29(3):280-2. doi: 10.4103/0255-0857.83913.
5
Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.
Int J Mol Sci. 2010 Jul 7;11(7):2670-80. doi: 10.3390/ijms11072670.
6
Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.
Int J Tuberc Lung Dis. 2009 Sep;13(9):1154-60.
7
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Chest. 2000 Mar;117(3):744-51. doi: 10.1378/chest.117.3.744.
Zotero 插件